Access is application-based. Select your tier, apply, and our team reviews within 48 hours.
AimwellBio has three distinct access models. Individual professionals buy personal intelligence access. Organizations buy governed team workflows. FHIN contributors join a credentialed network layer. If you are not sure, start with guided intake.
Physicians, researchers, clinicians, independent experts, consultants, and contributors using personal professional intelligence access.
I am an individual professional →Biopharma teams, health systems, compliance groups, investors, and enterprise buyers needing multi-user governance and reporting.
I represent a company or team →A credentialed network participation layer for expert review, professional signal interpretation, and founding-member onboarding.
I want to join FHIN →Answer a short intake and AimwellBio routes you to the right lane without forcing a pricing guess.
Help me choose →You do not have to reverse-engineer a feature table. Pick the line that sounds like your week, and we’ll route you to the tier built for that work, with honest labels on what is active today and what activates during onboarding.
You live in the evidence. Member gives you AIMN:VERDICT on a regular cadence, with a private vault and branded export in activation. Start here and move up if your volume grows.
Take me to Member →You answer to a room. Shield is built for the person who needs every signal in a board memo to be defensible. Competitor monitoring activates during onboarding.
Take me to Shield →You need seats, a shared decision trail, and review before activation. Command is sales-assisted and configured with Aimwell review, not a self-serve checkout.
Request Command access →Start as an Observer, sample verdicts with full citation-resolution gating, no payment, no sales call. The reference tier for seeing the standard first.
Start as an Observer →Click any biopharma entity, receive a sourced verdict in ~90 seconds, PROCEED, DELAY, or KILL, with citation-resolution gating. See live demo →
Most individual professionals start with Member at $199/month. Users who need category monitoring start with Signal at $279/month.
"I belong." Free after one-time approval. Start here. Sample 5 entities with full citation-resolution gating, no payment, no sales call.
One verified intelligence source per day, traceable to origin. For the cost of a single advisory hour.
"I can verify." Verdict checks, source trails, saved signals, and a basic archive. For analysts, regulators, and clinicians who run AIMN:VERDICT against named biopharma entities on a regular cadence. Without Member, you can see signals but not verify them.
Founding cohort capacity is reviewed manually. Locked-for-life pricing and vault write access. An engineering Slack invitation and methodology-acknowledgement review are initiated during onboarding, subject to eligibility.
Pharmaceutical intelligence sovereignty for nations that cannot depend entirely on external visibility.
"I can monitor." Watchlists, an expanded feed, digests, alerts, and the signal archive. Your first layer of verified clinical and regulatory signal protection.
"I can protect decisions." Risk flags, dossiers, regulatory movement, confidence history, and advanced exports. Dossiers unlock with Shield. Track risk patterns, regulatory movement, and company/category intelligence in one place. Daily intelligence protection for professionals who cannot afford to be surprised. Shield is currently available by request while dossier and risk-room workflows are being activated. The $449/mo price stands, access is granted by request rather than instant checkout.
"I can run intelligence workflows." Decision rooms, briefing exports, team workflow, and the Command dashboard. Decision rooms unlock with Command. Turn signals, dossiers, and verdicts into board-ready intelligence workflows. Command deployments are configured with Aimwell review before activation, not self-serve checkout.
What is your team currently spending on intelligence tools that do not source-trace their outputs?
Plus: 30-day Verdict Refund Pledge on Signal/Shield/Command. If the signal that mattered was not flagged, we refund the month and you keep the data you generated. See full policy →
Hand us anything your team is about to use. We return a source-risk review with every citation traced. No sales call. No follow-up sequence. The review itself is the conversation.
Most teams do not lose because they lacked data. They lose because the intelligence behind the next decision cannot be defended when someone asks where it came from.
Start With The Risk Brief →Teams searched documents, reviewed guidance updates, followed trial movement, tracked competitors, and built internal briefs by hand. Slow but auditable. Every claim had a paper trail.
Speed. The same brief that took a week now takes minutes. The trade-off: unsupported claims, stale guidance, missing context, and incomplete summaries can now move into serious decisions before anyone challenges them.
AimwellBio is the verification layer that sits between AI-generated intelligence and the decision someone signs their name to. Source-trace, adversarial review, confidence labels, institutional memory.
Seven ways unsupported scientific intelligence can enter regulatory, clinical, board, and investor workflows. Open to credentialed professionals. No sales sequence, no list-trading.